Literature DB >> 27430429

Cytotoxic effects of NF‑κB inhibitors in combination with anti‑herpes agents on Epstein‑Barr virus‑positive gastric carcinoma in vitro.

Paula Ordonez1, Athira Nandakumar1, Chihaya Koriyama1, Megumi Yamomoto2, Suminori Akiba1.   

Abstract

Epstein-Barr virus (EBV) infection in tumor cells is usually restricted to the latent form, indicating that the induction of viral lytic infection may present a novel approach for the treatment of EBV‑associated tumors. By contrast, EBV lytic replication is inhibited by high‑levels of nuclear factor (NF)‑κB, which suggests that NF‑κB inhibitors may activate lytic replication from the latent form. In the current study, the addition of NF‑κB inhibitors (Bay11‑7082, Z‑LLF‑CHO and aspirin) was observed to induce the EBV lytic genes BZLF1, BRLF1 and BMRF1 in EBV‑positive gastric cancer (GC) cells. Both EBV‑positive and ‑negative GC cells were treated with different concentrations of anti‑herpes agents and the cytotoxic effects were measured at different time points following induction of EBV lytic replication. A marginal dose‑ and time‑dependent reduction in cell viability was observed for EBV‑positive and‑negative GC cells. The cytotoxic effects of NF‑κB inhibitors on EBV‑positive GC cells were enhanced by the addition of the anti‑herpes agents, ganciclovir, acyclovir, foscarnet and brivudine (P<0.05). However, there was no significant synergistic effect on EBV‑negative GC cells. The combination of 5 mM aspirin and ganciclovir exhibited the highest cytotoxic effect in EBV‑positive GC cells (CC50=7.2 µg/ml).

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27430429     DOI: 10.3892/mmr.2016.5496

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  1 in total

1.  Medical History, Medication Use, and Risk of Nasopharyngeal Carcinoma.

Authors:  Xiling Xiao; Zhe Zhang; Ellen T Chang; Zhiwei Liu; Qing Liu; Yonglin Cai; Guomin Chen; Qi-Hong Huang; Shang-Hang Xie; Su-Mei Cao; Jian-Yong Shao; Wei-Hua Jia; Yuming Zheng; Jian Liao; Yufeng Chen; Longde Lin; Ingemar Ernberg; Guangwu Huang; Yi Zeng; Yi-Xin Zeng; Hans-Olov Adami; Weimin Ye
Journal:  Am J Epidemiol       Date:  2018-10-01       Impact factor: 4.897

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.